



## Curriculum Vitae

### Personal information **Amina Taleb**

#### Work experience

---

1. Employer: Groupe Hospitalier Sud Ile\_de\_France
  - Start date: 2017
  - End date:
  - Position: Head of Oncology Department
  - Activities: Expert ANSM (French Medicines Agency) since 2017 - Expert EMA\_SAG (Scientific Advisory Group Oncology) since 2021
  - Country: France
2. Employer: APHP \_ Paris University Hospitals
  - Start date: 042013
  - End date: 122016
  - Position: Oncologist
  - Activities:
  - Country: France
3. Employer: Le Mans Hospital
  - Start date: 2011
  - End date: 2013
  - Position: Oncologist & Head of Clinical Research Centre
  - Activities:
  - Country: France
4. Employer: APHP University Hospital
  - Start date: 1992
  - End date: 1998
  - Position: Resident in Oncology
  - Activities:
  - Country: France
5. Employer: Bristol Myers Squibb – Institut de Recherche Pierre Fabre – Celgene International (Research & Development)
  - Start date: 2000
  - End date: 2010
  - Position: Medical Director \_ R&D
  - Activities: Clinical Development of Anticancer Agents in Solid tumours.
  - Country: France

#### Education and training

---

1. Subject:
  - Start date: 1992
  - End date: 1995
  - Qualification: Oncology – Paris VI University, 1995
  - Organisation:
  - Country: France
2. Subject:
  - Start date:
  - End date:
  - Qualification: Methodology in Drug Clinical Trials, Paris University VI, 1997
  - Organisation:
  - Country: France
3. Subject:
  - Start date:
  - End date:
  - Qualification: Statistics Applied to Clinical Research, Paris University VI, 1998
  - Organisation:
  - Country: France
4. Subject:
  - Start date:
  - End date:
  - Qualification: Clinical Toxicology & Pharmacology, Paris University VII, 1999
  - Organisation:
  - Country: France

#### Additional information

---

##### Publications

Recent Publications from 2017

**Tumor Flare Reaction in Cancer Treatments** : A Systematic Review **Amina B. Taleb**, Oncology Department, Groupe Hospitalier Sud Ile de France, Paris \*Anti\_Cancer Drugs 2019, vol30:953–958 \*Annals of Oncology, volume 28, Issue Suppl\_5, 18 September 2017 (ESMO 2017 Poster 1166) \*J Clin Oncol 35, 2017 (suppl; abstr e18258) ASCO Annual Meeting 2017

**Oncology Drug Approval, Questioning efficacy evidence** **Amina B. Taleb**, Oncology Department, Groupe

Hospitalier Sud Ile de France, Paris J Clin Oncol 36, 2018 (suppl; abstr e18888) ASCO Annual Meeting 2018

**Evaluation of Clinical Trials in Onco\_haematology: A New Method Based on Risk Analysis and Multidisciplinarity** J. Lapière, C. Christen, G. Kerouani, A. Monard, F. Turcry, F. Grude, V. Gazin, M. Burbank, P. Chocarne, **A. Taleb B**, L. Belgodère, L. Brunel, C. Chu, C. Deligny, E. Ake, S. Gonçalves, P. Bouheret, S. Barbou\_des\_Courières, I. Sainte\_Marie, G. Guyader, L. Boudali & N. Albin Therapeutic Innovation & Regulatory Science volume 55, pages 601–611 (2021)

**Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019** Fiona Y.\_V. Pham, Emmanuelle Jacquet, **Amina Taleb**, Adrien Monard, Ghania Kerouani\_Lafaye, Florence Turcry, Liora Brunel, Françoise Grudé, Isabelle Yoldjian, Isabelle Sainte\_Marie, Lotfi Boudali, Jean\_Yves Blay, Nicolas Albin. International Journal of Cancer. 2022;1–10. doi:10.1002/ijc.34129

## Projects

### Anticancer Drug Development (Pharma)

Medical Director, International, Solid Tumors, 2000 to 2010

Bristol Myers Squibb – Institut de Recherche Pierre Fabre – Celgene International

Drug Development Plan. Designing and management of clinical studies, protocols and clinical/regulatory reports & filings. In compliance with SOPs, FDA/EMA regulations and ICH/GCP.

## Memberships

- American Society of Clinical Oncology ASCO
- European Society for Medical Oncology ESMO
- French Group GI Oncology FFCD

## Other Relevant Information